Exclusive Summary

• - Strong hospital demand in invasive aspergillosis and mucormycosis with rising high‑risk populations enables rapid entry into multiple countries via distribution.
• - US/EU generic entry expected around 2027; virtually no injectable generics now, leaving a high‑barrier, low‑competition window.
• - Clear clinical value: non‑inferior to voriconazole with better tolerability, only azole labeled for mucormycosis in US/EU, cyclodextrin‑free IV suitable for renal impairment.
• - China first‑generic with CPP and full audit/registration support fits fast‑track filings in MENA/LatAm/SEA markets that accept China CPP.
• - Potential 30–60% price reduction vs originator, delivering substantial per‑course savings and strong tender competitiveness.

Asset Materials

Contact Us for Full Materials